Marisa Wexler, MS, senior science writer —

The U.S. Food and Drug Administration (FDA) has lifted its hold on clinical trials of deucrictibant for the on-demand treatment of hereditary angioedema (HAE). The therapy’s developer Pharvaris now expects to resume RAPIDe-2 (NCT05396105), a long-term extension study evaluating PHVS416, an immediate-release capsule formulation of deucrictibant,…

People with hereditary angioedema (HAE) tend to experience fewer emergency room visits and hospitalizations after starting treatment with Haegarda or Takhzyro (lanadelumab), a new analysis indicates. Despite the decreasing rates, some patients still experience health emergencies while on these therapies, which researchers said highlights the burden of…

On-demand treatment with the experimental oral therapy PHVS416 was found to quickly and effectively ease symptoms of swelling attacks for people with hereditary angioedema (HAE) in a Phase 2 clinical trial. PHVS416 worked within hours of dosing, providing “clinical meaningful” reductions in swelling symptoms, according to researchers. Pharvaris,…

Over the months after a single treatment with the experimental gene-editing therapy NTLA-2002, nine of 10 people with hereditary angioedema (HAE) in a Phase 1/2 trial have been free from swelling attacks. Three patients with high pretreatment attack rates, ranging from 4.4 to 16.8 each month, have gone without…

Birth control pills can induce life-threatening swelling attacks in people with hereditary angioedema (HAE), according to a case report. “We highlight the importance of obtaining a thorough family history regarding any HAE attack before initiation of [oral contraceptives], as this care may be lifesaving,” researchers wrote. The report, “…

Ionis Pharmaceuticals has finished enrollment in a Phase 3 clinical trial testing the ability of its experimental therapy donidalorsen to prevent swelling attacks in people with hereditary angioedema (HAE) types 1 or 2. Results from the placebo-controlled study, dubbed OASIS-HAE (NCT05139810), are expected in the first half…

An experimental gene-editing therapy for hereditary angioedema (HAE), called NTLA-2002, has been administered to the first participant in the Phase 2 portion of a clinical trial, according to its developer, Intellia Therapeutics. “We are pleased to announce dosing has begun in the Phase 2 study of NTLA-2002,”…

A pregnant woman with type 3 hereditary angioedema (HAE) had potential swelling attacks effectively controlled during both pregnancy and breastfeeding with the use of subcutaneous or under-the-skin injections of a plasma-derived C1 esterase inhibitor (C1-INH), according to a case report from Spain. Researchers say this may be the first…

A woman with colon cancer developed angioedema as a side effect of treatment with an immune checkpoint inhibitor (ICI), a recently developed type of cancer immunotherapy. Researchers advised that “clinicians, pharmacists, and patients should be aware of this rare side effect of ICIs,” adding that facial angioedema can be…

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to NTLA-2002, an experimental gene-editing therapy that Intellia Therapeutics is developing to treat hereditary angioedema (HAE). RMAT designation is granted to therapies with the potential to treat, reverse, or cure serious or life-threatening…